Rezdiffra (Resmetirom) Tablets – 80 mg

Description

Rezdiffra (Resmetirom) Tablets – 80 mg

Generic Name: Resmetirom
Brand Name: Rezdiffra
Strengths Available: 80 mg 
Form: Oral Tablet
Pack Size: 30 tablets per bottle
Manufacturer: Madrigal Pharmaceuticals
Distributed by: NP Molecule

---

Indications:

Rezdiffra (Resmetirom) is indicated for the treatment of:

• Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with liver fibrosis (Stages F1-F3) in adults

This is the first and only FDA-approved therapy for NASH, offering a groundbreaking option for liver health management.

---

Pharmacology:

Resmetirom is a selective thyroid hormone receptor-β (THR-β) agonist, specifically designed to:

• Reduce liver fat content

• Decrease inflammation and fibrosis in NASH

• Improve lipid profiles, including LDL-C, triglycerides, and ApoB

By targeting THR-β in the liver, Rezdiffra delivers its effects without affecting the heart or bones, which are more responsive to THR-α.

---

Dosage & Administration:

• Starting dose: 80 mg orally once daily

• May be increased to 100 mg once daily based on clinical response and tolerability

• Should be taken with food for better absorption

• Tablets should be swallowed whole, not split or crushed

---

Drug Interactions:

• Minimal CYP enzyme involvement – fewer drug interactions

• May have additive effects with lipid-lowering therapies (e.g., statins)

---

Contraindications:

• Known hypersensitivity to Resmetirom or any tablet components

• Severe hepatic impairment or cirrhosis (not recommended for F4 fibrosis)

---

Side Effects:

• Common: Diarrhea, nausea, fatigue, headache, abdominal pain

• Serious (rare): Increased liver enzymes, muscle cramps, hypersensitivity reactions

---

Pregnancy & Lactation:

• Limited data available — not recommended unless absolutely necessary

• Breastfeeding should be avoided due to unknown excretion in breast milk

---

Precautions & Warnings:

• Regular monitoring of liver enzymes, lipid profile, and thyroid function recommended

• Not a weight loss medication

• Avoid use in patients with cirrhosis or decompensated liver disease

---

Overdose Effects:

• Potential for hyperthyroid-like symptoms (e.g., palpitations, anxiety)

• Supportive care recommended in case of overdose

---

Therapeutic Class:

• Selective THR-β Agonist / NASH Therapy

---

Storage Conditions:

• Store below 30°C

• Keep bottle tightly closed and protected from moisture

• Keep out of reach of children

---

Product Category:

Hepatology / Metabolic Liver Disease / NASH Treatment